New radioactive therapy shows promise for Hard-to-Treat gut cancers
NCT ID NCT07404176
First seen Feb 19, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This study tests a new radioactive drug called Terbium-161 DOTATATE in 20 adults with advanced neuroendocrine tumors that have stopped responding to standard treatment. The drug delivers radiation directly to cancer cells while sparing healthy tissue. The goal is to see if it can control tumor growth and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITINGNavi Mumbai, Maharashtra, 410210, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tata Memorial Hospital, Mumbai, India
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.